Zydus Lifesciences is reportedly close to buying a US oncology drug maker in a deal valued at $100 to $150 million. The acquisition is expected to help the Indian company build its own distribution network for anti-cancer drugs in the US, while also bringing along the target’s biologic drug pipeline. A deal is expected soon.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
